Advertisement
Organisation › Details
Fujifilm Cellular Dynamics International Inc. (FCDI)
Fujifilm Cellular Dynamics, Inc. (FCDI), a wholly owned subsidiary of Fujifilm Corporation, is a leading developer and supplier of human cells used in discovery, toxicity testing and regenerative medicine applications. Leveraging technology that can be used to create induced pluripotent stem cells (iPSCs) and differentiated tissue-specific cells from any individual, FCDI is committed to advancing life science research and transforming the therapeutic development process in order to fundamentally improve human health. The company's inventoried iCell® products and donor-specific MyCell® Products are available in the quantity, quality, purity and reproducibility required for drug and cell therapy development. *
Start | 2004-01-01 established | |
End | 2019-07-01 renamed before | |
Group | Fujifilm (Group) | |
Predecessor | Cellular Dynamics International Inc. (CDI) | |
Industry | iPSC technology (induced pluripotent stem cell technology) | |
Industry 2 | drug discovery services | |
Region | Madison, WI | |
Country | United States (USA) | |
City | n. a. Madison, WI | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | D: 101 to 500 (2014-12-31) |
Currency | USD | |
Annual sales | 16,700,000 (revenues, global (2014) 2014-12-31) | |
* Document for »About Section«: Bayer AG. (7/1/19). "Press Release: Century Therapeutics Launches with USD 250M Financing for induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform". Leverkusen, Philadelphia, PA & Tokyo. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Fujifilm (Group)
- [1] Fujifilm Corporation. (11/22/22). "Press Release: Fujifilm Invests $188 Million in New Cell Culture Media Manufacturing Facility". Tokyo....
- [2] Fujifilm Diosynth Biotechnologies UK Ltd.. (12/2/21). "Press Release: Fujifilm Diosynth Biotechnologies Confirms £400 Million Investment Plans to Create the Largest Multi-modal Biopharmaceutical Manufacturing Site in the United Kingdom". Billingham....
- [3] TreeFrog Therapeutics SAS. (2/5/20). "Press Release: TreeFrog Therapeutics Brings in Senior Profiles to Drive the Advent of High-quality and Affordable Allogenic Cell Therapies". Bordeaux....
- [4] Selexis S.A.. (1/9/20). "Press Release: Selexis Promotes Dr. Yemi Onakunle to Chief Business Officer". Geneva....
- [5] Fujifilm Diosynth Biotechnologies U.S.A. Inc.. (11/14/19). "Press Release: Fujifilm Diosynth Biotechnologies Announces $55 Millionn USD Investment to Expand Gene Therapy Development Capabilities". College Station, TX....
- [6] Fujifilm Corporation. (11/14/19). "Press Release: Fujifilm Announces Expansion of its Biopharmaceutical Contract Development and Manufacturing Business". Tokyo....
- [7] Biogen Inc.. (3/12/19). "Press Release: Biogen Enters Into an Agreement to Sell Its Large-Scale Biologics Manufacturing Site in Hillerød, Denmark to Fujifilm". Cambridge....
- [8] Fujifilm Irvine Scientific, Inc.. (1/2/19). "Press Release: Accelerating the Growth of the Cell Culture Media Business. Leading Cell Culture Media Company Changes Name to »Fujifilm Irvine Scientific, Inc.«"....
- [9] Fujifilm Corporation. (12/19/17). "Press Release: Fujifilm Acquires Equity Stake in EdiGene, a Drug Discovery Startup"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top